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Introduction: We tested the hypothesis that higher mid-regional pro-adrenomedullin (MR-proADM), carboxy-terminal
pro-endothelin-1 (CT-proET-1), procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations would be
associated with increased prediction of mortality risk scores.
Methods: Prospective observational study set in two pediatric intensive care units (PICUs). Two-hundred-thirty-eight
patients were included. MR-proADM, CT-proET-1, PCT and CRP levels were compared between children with PRISM III
and PIM 2 > p75 (Group A; n = 33) and the rest (Group B; n = 205).
Results: Median (range) MR-proADM levels were 1.39 nmol/L (0.52–12.67) in group A versus 0.54 (0.15–3.85) in group B
(P < 0.001). CT-proET-1 levels were 172 pmol/L (27–500) versus 58 (4–447) (P < 0.001). PCT levels were 7.77 ng/mL
(0.34–552.00) versus 0.28 (0.02–107.00) (P < 0.001). CRP levels were 6.23 mg/dL (0.08-28.25) versus 1.30 mg/dL (0.00-42.09)
(P = 0.210). The area under the ROC curve (AUC) for the differentiation of group A and B was 0.87 (95% CI:0.81–0.821) for
MR-proADM, 0.86 (95% CI:0.79–0.92) for CT-proET-1 and 0.84 (95% CI:0.74–0.94) for PCT. A MR-proADM> 0.79 nmol/L had
93% sensitivity and 76% specificity to differentiate groups, whereas a CT-proET-1 > 123 pmol/L had 77% sensitivity and
84% specificity, and a PCT concentration > 2.05 ng/mL had 80% sensitivity and specificity.
Conclusions: In critically ill children, high levels of MR-proADM, CT-proET-1 and PCT were associated with increased
prediction of mortality risk scores. MR-proADM, CT-proET-1 and PCT concentrations higher than 0.80 nmol/L,
123 pmol/L and 2 ng/mL, respectively, could be used by clinicians to identify critically ill children at higher
prediction of risk death scores.Introduction
Having available tools to determine the prognosis of
critically ill children at admission to the Pediatric Intensive
Care Unit (PICU), or during the first 24 hours after admis-
sion, constitutes a clinical necessity. The better evaluated
tools have been scales developed to estimate the mortality
risk depending on clinical signs and routine analysis. The
most used scales are Pediatric Risk of Mortality (PRISM
III) and Pediatric Index of Mortality (PIM 2) [1-5].
Procalcitonin (PCT) was initially used to determine
sepsis diagnosis [6] and, afterwards, to help in severity
classification of patients [7] and to guide antibiotic* Correspondence: corsino.rey@sespa.princast.es
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reproduction in any medium, provided the ortreatment duration [8]. C-reactive protein (CRP) rises in
response to infectious and inflammatory diseases and
shows greater elevations in serious bacterial [6,7,9,10] in-
fections. CRP has been shown to be elevated in adult pa-
tients with a higher mortality risk [11,12].
Recently, new readily measurable circulating bio-
markers have been described as an additional tool for
severity classification of septic patients and prediction
of mortality in critically ill patients. Adrenomedullin
(ADM) and endothelin-1 (ET-1) are included among these
new biomarkers [13-21]. ADM is mainly released from
endothelial cells, acts as a potent vasodilator and has natri-
uretic effects [22,23]. Other ADM properties include a
reduction in endothelial permeability [24], bactericidal. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[25]. ET-1 is a potent vasoconstrictor agent, synthesized
mainly by endothelial cells. Elevated levels of ET-1 were
found during systemic infections [16] and ET-1 levels cor-
related with mortality risk [21]. Recently, assays have
become available to determine circulating mid-regional
pro-adrenomedullin (MR-proADM) and carboxy-terminal
pro-endothelin-1 (CT-proET-1) concentrations [26,27].
These peptides are co-synthesized with ADM and ET-1,
respectively, and have the advantage of a longer half-life,
lack of bioactivity and lack of protein binding, which
makes them more suitable for daily practice [28]. Briefly,
on admission, concentrations of MR-proADM and CT-
proET-1 were shown to increase gradually in correlation
with severity ranging from systemic inflammatory re-
sponse syndrome (SIRS) to severe forms of sepsis or with
the pneumonia severity index (PSI) [13,14,21].
So far, no data are available for pediatric patients.
Therefore, the objective of our study was the investiga-
tion of MR-proADM, CT-proET-1, PCT and CRP levels
in a well-defined cohort of consecutive PICU patients to
test the hypothesis that higher plasma concentrations
would be associated with increased prediction of mortal-
ity risk scores in critically ill children. As a secondary
objective, we also tested the hypothesis that higher
plasma marker concentrations would be associated with
a number of organ failures >1.
Materials and methods
We designed a prospective observational study set in
two PICUs of University Hospitals (eight-bed PICU of
Hospital Universitario Central de Asturias in Oviedo
and eleven-bed PICU of Hospital Universitario Gregorio
Marañón in Madrid). The study protocol was approved by
the Hospital Ethics Committee of Hospital Universitario
Central de Asturias. Written informed consent was ob-
tained from the patients’ parents or guardians and from
children above 12 years old.
The study was conducted in 254 consecutive pa-
tients, age <18 years, who were admitted to one of
these PICUs. The exclusion criteria were no blood ex-
traction during the first 12 hours and parents, guard-
ians or children above 12 years old who did not
consent to participate. A total of 56 patients were ex-
cluded for these reasons. The following variables were
prospectively recorded at admission: age, weight, cause of
PICU admission, diagnosis and previous diseases. Respira-
tory rate (RR), heart rate (HR), blood pressure (BP), O2
saturation (Sat O2), urine rate and administration of
vasopressor agents were recorded hourly. Radiographic
and microbiologic diagnostics were performed when
indicated. Blood cultures were performed when there
was clinical suspicion of infection or if a patient’s
temperature was >38°. The PIM 2 value was calculated atadmission and PRISM III during the first 12 hours after
admission, as it was the normal clinical practice. PIM
2 and PRISM III had been previously validated in
both PICUs [1]. Biochemical routine determinations
including CRP and PCT were performed during the
first 12 hours after admission. Venous blood samples
were collected in tubes containing ethylenediaminetet-
raacetic acid (EDTA). A plasma aliquot was frozen
and stored at −80°C for further determination of MR-
proADM and CT-proET-1.
Mortality risk groups
Patients were divided into two groups according to mor-
tality risk scores. The higher score risk mortality group
(Group A) included patients with a PIM 2 and PRISM
III score > p75 (n = 33); the lower score risk mortality
group (Group B) included patients with a PIM 2 and/or
PRISM score ≤ p75 (n = 221).
Number of organ failures groups
Patients were divided into two groups according to the
number of organ failures (cardiovascular, respiratory,
neurological, hematological, renal and hepatic) following
conference consensus criteria [29]. Group A1 included pa-
tients with a number of organ failures >1 (n = 71) whereas
group B1 included patients with <2 organ failures (n = 182).
Infectious subgroups
Patients were classified as infectious or non-infectious
subgroups during the first 24 hours after admission ac-
cording to the definitions of the European Society of In-
tensive Care/Society of Critical Care Medicine [30]
modified for use in pediatrics [29].
Measurement of CRP, PCT, MR-pro-adrenomedullin and
CT-proET-1
MR-proADM, CT-proET-1 and PCT were measured in
EDTA plasma using a sandwich immunoassay (TRACE
technology; Brahms, Hennigsdorf, Germany). Analytical
detection limits were 0.08 nmol/L for pro-ADM, 0.4
pmol/L for CT-proET-1 and 0.02 ng/mL for PCT.
Plasma CRP was measured on a Modular Analytics
Cobacs 6000 (Roche diagnostics, Indianapolis, IN, USA)
by an immunoturbidimetric technique. Analytical detec-
tion limit was 0.07 mg/dL.
Statistical analysis
Patients’ clinical and biological parameters were described
using frequencies, percentages, medians and ranges. The
two groups of patients (A versus B; A1 versus B1) were
compared using the non-parametric Mann–Whitney U-
test for continuous variables and the exact χ2 test for cat-
egorical data. Receiver operating characteristic (ROC)
curves and the respective areas under the curve (AUC)
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tervals were also reported. The AUCs were compared in
order to establish the marker with the highest global diag-
nostic efficiency to calculate mortality risk scores and
number of organ failures. The Youden criterion was used
to establish threshold (cut-off) values and to build decision
rules to differentiate groups A versus B and A1 versus B1.
In addition, in order to measure the quality of these deci-
sion rules, a leave-one-out method was developed and the
obtained sensitivity, specificity, positive predictive (PPV)
and negative predictive (NPV) values are reported. Trying
to find a combined score of biomarkers model, a multivari-
ate logistic regression analysis which included a stepwise
method based on the likelihood ratio has been explored. A
P-value <0.05 was considered statistically significant.Table 1 Demographic, clinical, laboratory and markers data
Demographic and clinical characteristics Group A (n = 33)
Age at admission (months) 19 (50)
Weight (kg) 11.0 (10.5)
Male sex (%) 60,6
Admission diagnosis Group A (n = 33)
Postoperative 1 (1.7)







PRISM III (absolute value) 13.0 (7.5)
PIM 2 (%) 4.2 (6.7)
Laboratory data Group A (n = 33)
pH 7.26 (0.16)
Bicarbonate (mEq/L) 16.8 (8.9)
Lactate (mmol/L) 1.20 (1.13)
Platelets (X1000/mm3) 228.5 (240.4)
Markers Group A (n = 33)
CRP (mg/dl) 6.23 (15.5)
PCT (ng/ml) 7.76 (25.81)
MR-proADM (nmol/l) 1.39 (1.59)
CT-proET-1 (pmol/l) 172.3 (82.70)
Markers Group A1 (n = 71)
CRP (mg/dl) 9.57 (15.4)
PCT (ng/ml) 4.91 (32.7)
MR-proADM (nmol/l) 1.380 (1.60)
CT-proET-1 (pmol/l) 159.09 (97.40)
Group A: Higher score risk mortality group. Group B: Lower score risk mortality grou
failures <2; admission diagnosis is described by the absolute and relative values (%
CRP: C-reactive protein; CT-pro-ET1: C-terminal-pro-endothelin-1; PCT:procalcitonin;Results
Baseline characteristics
Two hundred fifty four patients were included in the
study (150 boys and 104 girls).
Baseline demographic, clinical and laboratory charac-
teristics of the patients are shown in Table 1. More than
half were younger than four years old. The main reasons
for PICU admission were postoperative, cardiac surgery,
and respiratory and infectious disease. A total of five pa-
tients (2%) died during the PICU hospitalization. Pa-
tients with higher risk of mortality scores (group A)
were younger than group B patients.
PCT, MR-proADM and CT-proET-1 plasma levels
were significantly higher in patients with higher risk of
mortality scores (group A) (Table 1). CRP plasma levelGroup B (n = 221) P-value Overall population N = 254
45 (99) 0.012 44 (81)
16.0 (22.0) 0.005 15.0 (17.4)
58,8 0,853 59,1
Group B (n = 221) P-value Overall population N = 254
59 (98.7) <0.001 60 (23.6)
26 (55.3) 0.560 47 (18.5)
44 (97.8) <0.001 45 (17.7)
35 (87.5) <0.001 40 (15.7)
15 (88.2) 0.002 17 (6.7)
0 (0) - 10 (3.9)
8 (88.9) 0.039 9 (3.6)
24 (92.3) <0.001 26 (16.8)
2.0 (5.0) <0.001 3.0 (8.0)
0.8 (1.0) <0.001 0.9 (1.73)
Group B (n = 221) P-value Overall population N = 254
7.35 (0.10) 0.001 7.34 (0.10)
21.9 (3.9) 0.030 21.8 (3.9)
0.90 (1.10) 0.027 1.00 (1.10)
289.0 (169.0) 0.043 281.0 (168.0)
Group B (n = 221) P-value Overall population N = 254
1.30 (8.8) 0.210 1.47 (10.1)
0.27 (1.36) <0.001 0.34 (1.83)
0.53 (0.41) <0.001 0.58 (0.39)
58.47 (56.50) <0.001 67.59 (53.13)
Group B1 (n = 182) P-value Overall population N = 253
1.07 (7.5) <0.001 1.47 (10.1)
0.20 (1.28) <0.001 0.34 (1.83)
0.471 (0.28) <0.001 0.58 (0.39)
52.65 (41.00) <0.001 67.59 (53.13)
p; Group A1: number of organ failures >1. Group A2: number of organ
); the rest of the variables are described by median and interquartile range.
MR-pro-ADM: midregional-pro-adrenomedullin.
Figure 1 ROC curves for PCT, MR-proADM, and CT-proET-1 in
prediction of risk of mortality scores. Legend: CRP (C-reactive
protein, mg/dl), PCT (procalcitonin, ng/ml), Pro-ADM (midregional-
pro-adrenomedullin, nmol/l), Pro-ET1 (C-terminal-pro-endothelin-1,
units: pmol/l).
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proADM and CT-proET-1 plasma levels were signifi-
cantly higher in patients with two or more number of
organ failures (group A1) (Table 1).
Value for CRP, PCT, MR-proADM and CT-proET-1 in
prediction of risk of mortality scores
To evaluate the value for CRP, PCT, MR-proADM and
CT-proET-1 in the prediction of risk of mortality scores,
ROC curve analysis was performed for each pro-
hormone (Table 2 and Figure 1). The optimal cut-off
value of PCT for predicting risk of mortality scores was
2.05 ng/ml, showing a similar sensitivity and specificity
of 80%. A MR-proADM concentration higher than
0.79 nmol/L had 93% sensitivity and 76% specificity,
whereas a CT-proET-1 concentration higher than 123
pmol/L had 77% sensitivity and 84% specificity.
Value for CRP, PCT, MR-ProADM and CT-pro-ET1 in
prediction of number of organ failures
ROC curve analysis was performed for each biomarker
(Table 2 and Figure 2). A CRP level of 3.76 mg/dL
showed a sensitivity of 75% and a specificity of 65%; a
PCT level of 4.12 ng/mL gave a sensitivity of 61% and a
specificity of 88%; a MR-proADM concentration higher
than 0.77 nmol/L had 91% sensitivity and 85% specificity,Table 2 CRP, PCT, MR-pro-ADM and CT-pro-ET-1
measurements in prediction of risk mortality scores and
organ failure
Parameters AUC (95% interval confidence)
Risk mortality score Organ failure (+1)
CRP 0.608 (0.452 to 0.764) 0.713 (0.609 to 0.816)
PCT 0.839 (0.739 to 0.940) 0.804 (0.715 to 0.892)
Pro-ADM 0.866 (0.810 to 0.821) 0.922 (0.887 to 0.957)
CT-proET-1 0.853 (0.784 to 0.922) 0.915 (0.876 to 0.954)
Risk mortality score
Without infection With infection
CRP 0.753 (0.534 to 0.971) 0.468 (0.232 to 0.705)
PCT 0.955 (0.876 to 1.035) 0.710 (0.499 to 0.922)
MR-pro-ADM 0.886 (0.828 to 0.945) 0.869 (0.771 to 0.966)
CT-proET-1 0.893 (0.839 to 0.948) 0.856 (0.745 to 0.967)
Organ failure (+1)
Without infection With infection
CRP 0.770 (0.601 to 0.939) 0.634 (0.493 to 0.775)
PCT 0.868 (0.738 to 0.977) 0.739 (0.582 to 0.896)
MR-pro-ADM 0.943 (0.906 to 0.980) 0.901 (0.832 to 0.970)
CT-proET-1 0.967 (0.942 to 0.993) 0.804 (0.705 to 0.904)
Results are presented for the whole sample and for subgroups of patients with
and without infection. ROC curve analysis of CRP (C-reactive protein, mg/dl),
PCT (procalcitonin, ng/ml), MR-pro-ADM (midregional-pro-adrenomedullin,
nmol/l) and CT-pro-ET1 (C-terminal-pro-endothelin-1, pmol/l).whereas a CT-proET-1 concentration higher than 80
pmol/L had 90% sensitivity and 77% specificity.
Subgroups analysis
Patients were classified into infectious or non-infectious
subgroups during the first 24 hours after admission. We
performed a subgroup analysis of mortality risk scores
taking into account this classification (Table 2). In the
infectious subgroup a PCT level of 2.05 ng/mL gave aFigure 2 ROC curves for CRP, PCT, MR-proADM and CT-pro-ET-1
in prediction of number of organ failures. Legend: CRP (C-reactive
protein, mg/dl), PCT (procalcitonin, ng/ml), Pro-ADM (midregional-pro-
adrenomedullin, nmol/l), Pro-ET-1 (C-terminal-pro-endothelin-1, pmol/l).
Table 3 Sensitivity, specificity, positive predictive values
and negative predictive values of CPR, PCT, MR-proADM
and CT-pro-ET1
Parameters
PICU risk mortality score Organ failure (+1)
Se Sp PPV NPV Se Sp PPV NPV
CRP 0.416 0.640 0.072 0.942 0.583 0.642 0.192 0.914
PCT 0.700 0.798 0.167 0.979 0.610 0.569 0.169 0.910
MR-ProADM 0.900 0.758 0.337 0.982 0.897 0.850 0.693 0.956
CT-proET-1 0.710 0.741 0.386 0.954 0.884 0.768 0.592 0.946
PICU risk mortality score
Without infection With infection
Parameters Se Sp PPV NPV Se Sp PPV NPV
CRP 0.400 0.865 0.125 0.968 0.500 0.365 0.060 0.900
PCT 0.750 0.822 0.143 0.988 0.500 0.573 0.088 0.933
MR-proADM 0.863 0.817 0.422 0.974 0.875 0.701 0.233 0.982
CT-proET-1 0.773 0.866 0.472 0.960 0.625 0.833 0.278 0.956
Organ failure (+1)
Without infection With infection
Parameters Se Sp PPV NPV Se Sp PPV NPV
CRP 0.778 0.677 0.179 0.971 0.643 0.606 0.257 0.889
PCT 0.778 0.758 0.233 0.973 0.428 0.938 0.600 0.884
MR-proADM 0.898 0.877 0.759 0.952 0.895 0.742 0.500 0.961
CT-proET-1 0.918 0.894 0.789 0.962 0.842 0.492 0.320 0.917
Legend: Results obtained after applying a cross validation method to test the
quality of decision rules, presented for the whole sample and for subgroups
of patients with and without infection. CRP (C-reactive protein, mg/dl), PCT
(procalcitonin, ng/ml), MR-pro-ADM (midregional-pro-adrenomedullin, nmol/l),
CT-pro-ET-1 (C-terminal-pro-endothelin-1, pmol/l). Se: sensitivity. Sp: specificity.
NPV: negative predictive value. PPV: positive predictive value.
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proADM concentration higher than 0.80 nmol/L had
100% sensitivity and 70% specificity, whereas a CT-
proET-1 concentration higher than 80.57 pmol/L had
75% sensitivity and 86% specificity.
In the non-infectious subgroup a PCT level of 0.58 ng/
mL gave a sensitivity of 100 and a specificity of 82, a MR-
proADM concentration higher than 0.84 nmol/L had 91%
sensitivity and 82% specificity, whereas a CT-proET-1
concentration higher than 83.50 pmol/L had 91% sensitiv-
ity and 70% specificity.
We also performed an infectious versus non-infectious
subgroup analysis to differentiate the number of organ
failures (Table 2). In the infectious subgroup a PCT level
of 4.12 ng/mL gave a sensitivity of 71% and a specificity of
70%, a MR-proADM concentration higher than 0.81 nmol/
L had 84% sensitivity and 79% specificity, whereas a CT-
proET-1 concentration higher than 79.5 pmol/L had 79%
sensitivity and 66% specificity.
In the non-infectious subgroup a PCT level of 0.40 ng/
mL gave a sensitivity of 89% and a specificity of 77%, a
MR-proADM concentration higher than 0.77 nmol/L had
90% sensitivity and 91% specificity, whereas a pro-ET1
concentration higher than 87.3 pmol/L had 93% sensitivity
and 89% specificity.
Analysis of quality of decision rules: cross-validation
results
We performed a cross validation method to test the qual-
ity of decision rules. Results for the obtained sensitivity,
specificity, PPV and NPV values are reported in Table 3.
Combined score of biomarkers
We developed several scores with the best AUCs obtained
with the combination of two markers. The AUC for the
combination of MR-proADM and PCT in the prediction
of PICU risk of mortality scores was 0.935 (0.842 to
0.978) when the decision was based on the score S1 (S1 =
1.39 ·MR-proADM+ 0.01 · PCT) which with a threshold of
1.70 leads to a sensitivity of 90.0% and a specificity of 90.1%
(PPV and NPV were 34.6 and 99.3, respectively). The AUC
for the combination of MR-proADM and CT-pro-ET1 was
0.900 (0.858 to 0.942) for decision based on the score S2
(S2 = 0.77 ·MR-proADM+ 0.01 · CT-pro-ET1) which with a
cut-off value of 1.85 obtained a sensitivity of 90% and a spe-
cificity of 80.3% (PPV was 38.6% and NPV 98.3%). The
AUC for the combination of MR-proADM and PCT in
the prediction of more than 1 organ failure was 0.904
(0.848 to 0.981) when the decision was based on the score
S3 (S3 = 2.04 ·MR-proADM+0.02 · PCT) which with a
threshold of 2.00 achieved a sensitivity and a specificity of
82.6% and 89.2%, respectively (PPV of 52.8% and NPV of
97.2%). The AUC for the combination of MR-proADM and
CT-pro-ET1 was 0.945 (0.918 to 0.973) for the scoreS4 (S4 = 1.53 ·MR-proADM+0.03 · CT-pro-ET1); a cut-off
value of 3.65 yielded a sensitivity of 97.1% and a specificity
of 79.9% (PPV and NPV were 64.7% and 98.6%, respect-
ively). The combination of MR-proADM and CRP did not
improve MR-proADM accuracy.
Discussion
An important issue in pediatric critical care is the im-
provement of prognostic assessment. Markers that are
able to stratify critically ill children depending on the
risk of mortality could help physicians to make deci-
sions. To our knowledge, this is the first prospective
study in critically ill children which tries to identify vaso-
active biomarkers as outcome predictors. We have
shown that high levels of MR-proADM, CT-proET-1
and PCT are associated with increased risk of mortality
scores as well as increased risk of number of organ fail-
ures in a heterogeneous sample of critically ill children.
We cannot use mortality as the gold standard to differ-
entiate a patient’s prognosis because PICU mortality was
low in our sample. Therefore, we used other surrogate
markers of PICU outcome, such as mortality scores.
Numbers of organ failures are other criteria of severity
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the patients with a higher risk of mortality had two or
more number of organ failures.
Mortality risk
Children with higher risk of mortality scores were youn-
ger, and presented at admission with lower pH, bicarbon-
ate and platelets, and higher lactate (Table 1). Previous
studies have shown a higher risk of mortality in younger
children [1,31]. Lactate levels correlated with mortality in
postoperative cardiac surgery children [32,33] as well as
critically ill adult patients [34]. A low level of platelets cor-
related with mortality increase [35].
The main objective of our study was to identify bio-
markers as risk mortality predictors. CRP has been
shown to be elevated in adult patients with higher mor-
tality risk [11,12]. In agreement with other studies [9,10],
we found no significant differences in CRP concentra-
tions between group A and B patients. Slow CRP kinet-
ics could explain this finding. PCT levels increased in
direct relation to disease severity [7,36-38]. We found
that a PCT cut-off value of 2.05 ng/mL predicted risk of
mortality scores with 80% sensitivity and specificity.
When analyzing subgroups of patients, we found that
PCT was a better marker of mortality risk scores in the
non-infectious subgroup (Table 2). Cut-off level de-
creases to 0.58 ng/mL with higher sensitivity and specifi-
city. To explain this decrease in cut-off level and better
performance we have to take into account that in pa-
tients with bacterial infection PCT increase is due to
both infection and disease severity, whereas in patients
without infection the only reason for a PCT increase is
the acute inflammatory process from a high severity
shock, trauma and so on. Therefore, when bacterial in-
fection is absent a PCT increase could be directly related
to disease severity.
To date, few data are available regarding the potential
of vasoactive pro-hormones as biomarkers in mortality
risk determination. MR-proADM was evaluated as a se-
verity marker in septic adult patients with promising re-
sults [39]. Increased admission levels of MR-proADM in
critically ill patients have been associated with increased
mortality [39,40]. We found that MR-proADM can be
useful to identify critically ill children with different risk
of mortality scores. Areas under the ROC curve range
from 0.67 in the study of Schuetz et al. [15] to 0.87 in
the Wang et al. study [40] with an intermediate value of
0.81 in the study of Christ-Crain et al. [18] in patients
with sepsis and septic shock. We obtained a value of
0.86. Our MR-proADM cut-off value of 0.79 nmol/L
was similar to values of 0.95 described to predict mortal-
ity in community-acquired pneumonia patients [41] but
lower than the value of 3.9 nmol/L obtained by Christ-
Crain et al. [18] in septic patients. The reason could bedifferent patients and different methodology. In our pa-
tients, we tried to differentiate risk of mortality scores at
the level of p75 whereas Christ-Crain et al. [18] tried to
differentiate survival versus nonsurvival patients. We
only found a pediatric study in septic neonates comparing
MR-proADM levels between survivors and nonsurvivors.
MR-proADM levels were 5.22 nmol/L and 11.40 nmol/L,
respectively [42]. However, these values had to be analyzed
with caution due to other factors that can increase MR-
proADM in neonatal patients.
CT-proET-1 was also a good marker of mortality risk
with AUCs under the ROC curve similar to MR-
proADM. Brauner et al. [21] also found an association
between CT-proET-1 levels and mortality in septic shock
patients. Other adult studies did not find differences in
CT-proET-1 levels between survivors and non-survivors
[15,43].
Different from PCT, MR-proADM and CT-proET-1
areas under ROC curve were similar in patients with
and without infection. Moreover, PCT cut-off levels were
different in infectious versus non-infectious patients,
whereas MR-proADM and CT-proET-1 cut-off levels
were almost the same in both groups of patients. This is
an advantage for both vasoactive peptides that were not
influenced by the infectious situation of the patient.
Number of organ failures
The performance of biomarkers to identify patients with
two or more organ failures was similar to that previously
described for risk of mortality, except for CRP. We
found higher serum CRP levels in children from group
A1 versus B1. Lobo et al. [11] showed a higher incidence
of respiratory, renal and hematologic organ failures in
patients with CRP levels higher than 10 ng/mL. Our cut-
off value to differentiate groups A1 and B1 was 3.76 mg/dl.
Values for the areas under the ROC curve to differentiate
group A1 versus B1 were acceptable for CRP, good for
PCT and excellent for CT-proET-1 and MR-proADM
(Table 2 and Figure 2). PCT cut-off values of 4.12 ng/mL
were higher than previous values for mortality risk whereas
MR-proADM cut-off values of 0.77 nmol/L were similar
and CT-proET-1 cut-off values of 80.57 pmol/L were
lower. Several studies found a correlation between PCT
increase during the first 24 hours after admission [44] or
postoperative PCT increase [45] and number of organ fail-
ures. Ueda et al. [46] showed a correlation between MR-
proADM levels and the multiple organ failure score.
Analysis of quality of decision rules: cross-validation
results
As expected, the values of sensitivity, specificity, NPV
and especially PPV were lower after performing a cross-
validation test. However, the information given by the
markers, especially MR-proADM, appears to improve
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risk of mortality scores and more than one organ failure.
Combined score of biomarkers
The single marker with the greatest AUC was MR-
proADM. Combination of MR-proADM with each of the
other markers slightly improves diagnostic efficiency to dif-
ferentiate groups. We have developed several scores with
the best AUCs obtained with the combinations of MR-
proADM and PCT, and MR-proADM and CT-proET1.
Prognostic assessment
The additional value of information provided by bio-
markers when compared with scoring systems has to be
further evaluated in order to translate their measure-
ments into clinical practice. PRISM III and PIM 2 scores
have been validated for mortality risk stratification, but
tend to be used more for audit and research than clinical
decision making [1,3-5]. A rapidly available biochemical
test that provides similar prognostic information could,
therefore, be useful, for example, to help discussions about
prognosis with patients’ relatives and decisions regarding
earlier interventions. Future work should clarify whether
the increase of MR-proADM and CT-proET-1 in pediatric
patients with higher risk of mortality results from an up-
regulation of biomarker secretion in patients with differ-
ent organ failures. A rising PCT level is currently used as
an indicator that an infectious process is not under con-
trol and that better source control is required [47]. Future
work should clarify whether PCT at a low cut-off level
could be used for prognosis in non-infectious patients.
Our study has limitations. First, taking into account that
it was not sufficiently powered to pick up differences in
survival, we used other surrogate markers of PICU out-
come, such as mortality scores, against which the bio-
markers diagnostic criteria can be calibrated. Second, we
have performed an observational study that does not allow
drawing any conclusion concerning therapeutic interven-
tions. Third, this was a two-center study that includes
different groups of critically ill children. The value for bio-
markers in prediction of adverse outcome would be differ-
ent if the population was different. Fourth, biomarker
levels were analyzed during the first 12 hours after PICU
admission, but follow-up measurements were not avail-
able. Evolution of biomarker levels during the first admis-
sion days would have higher accuracy. However, an early
mortality prediction is more useful in clinical practice.
Fifth, the A and B groups were different in terms of diag-
nosis. We cannot totally rule out that this difference has
influenced biomarkers levels.
Conclusions
High levels of MR-proADM, CT-proET-1 and PCT were
associated with increased prediction of mortality riskscores. MR-proADM, CT-proET-1 and PCT concentra-
tions higher than 0.80 nmol/L, 123 pmol/L and 2 ng/mL,
respectively, could be used by clinicians to identify critic-
ally ill children at higher prediction of death risk score.
Key messages
 MR-proADM, CT-proET-1 and PCT levels during
the first 12 hours after PICU admission are
associated with increased prediction of mortality
risk score in critically ill children.
 The cut-off level to identify critically ill children at
higher score risk of death were 0.80 nmol/L for
MR-proADM, 123 pmol/L for CT-proET-1 and 2
ng/mL for PCT.
 The additional value of these combinations of
biomarker cut-off levels when compared with
scoring systems has to be further evaluated in order
to translate their measurement into clinical practice.
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